Meeting
2018 ASCO Annual Meeting
A phase 2, single-arm trial of neoadjuvant axitinb plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
Authors
Axel Bex
The Netherlands Cancer Institute, Amsterdam, Netherlands
Axel Bex , Johannes V. Van Thienen , Mariette Schrier , Kees Hendricksen , Christian U. Blank , John B. A. G. Haanen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03341845
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4604)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4604
Abstract #
TPS4604
Poster Bd #
421a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
First Author: Axel Bex
Poster
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity from first-line TKI plus IO therapies for advanced renal cell carcinoma.
First Author: David Joseph Benjamin
Poster
2020 Genitourinary Cancers Symposium
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
First Author: Roberto Iacovelli
Poster
2020 Genitourinary Cancers Symposium
Relative risk of hematological toxicities in patients with advanced renal cell carcinoma treated with upfront immune checkpoint inhibitors.
First Author: Nusrat Jahan